Study Title

Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients

Study Details

Description:

The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients.

Sponsor:

Institut Cancerologie de l'Ouest

Contacts:

Caroline ROUSSEAU, MD (Study Chair)

caroline.rousseau@ico.unicancer.fr

+ 33 240679931

Nadia ALLAM, PhD

nadia.allam@ico.unicancer.fr

+33 240679826

Government Study Link:

NCT04758780 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468